Do GLP-1s Affect Hot Flashes in Menopause?

There is no strong evidence that GLP-1 medications like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) directly cause hot flashes. Hot flashes are not listed among the common side effects in the major trials of these drugs, such as STEP 1 (NEJM 2021) for semaglutide or SURMOUNT-1 (NEJM 2022) for tirzepatide. The well-documented side effects are mostly digestive, including nausea, diarrhea, and constipation.

That said, many women start GLP-1 medications during their 40s and 50s, exactly when perimenopause and menopause are already causing hot flashes. So it is easy to start a new medication and then notice hot flashes, and to wonder if the drug is responsible, when in fact the timing simply overlaps with the menopause transition. Hormonal changes, not the medication, are usually the real driver.

There is also a practical wrinkle: some GLP-1 side effects, like flushing, sweating, or feeling warm after eating, can feel similar to a hot flash but have a different cause. Rapid changes in blood sugar or the body's response to a meal can produce warmth and sweating. If you are tracking symptoms, it helps to note what you were doing, eating, and feeling at the time, so you and your provider can tell genuine menopausal hot flashes apart from medication-related sensations. Understanding what actually triggers a hot flash makes this easier to sort out.

Yes, there is good evidence that losing weight can reduce hot flashes for many women, and this is the main way GLP-1 medications might indirectly help. Research has consistently linked higher body weight, especially more body fat, to more frequent and severe hot flashes. Body fat affects how the body regulates temperature and influences hormone levels, which may make vasomotor symptoms worse in women carrying extra weight.

The strongest evidence comes from a behavioral weight-loss study (Huang et al., Archives of Internal Medicine, 2010), part of a larger trial, which found that overweight and obese women who lost weight through diet and exercise reported significant improvements in their hot flashes compared with women who did not lose weight. The more weight women lost, the more their bothersome hot flashes tended to improve. Data from the SWAN study have similarly associated higher body mass index with greater vasomotor symptoms during midlife.

This is the key link to GLP-1 drugs. These medications produce substantial weight loss, often 15-20% of body weight in trials. If weight loss eases hot flashes, then it is reasonable to expect that some women on GLP-1s may notice their hot flashes become less frequent or intense as they lose weight, even though the drug is not targeting hot flashes directly. The effect is indirect, gradual, and varies from person to person, and it sits alongside the broader question of how GLP-1s perform during the menopause years.

GLP-1 medications and menopause symptoms get confused because they often appear at the same time and can produce overlapping sensations. Many women begin GLP-1 treatment in midlife, the same window when perimenopause brings hot flashes, night sweats, sleep problems, mood changes, and fatigue. When two things start close together, it is natural to blame whichever one is newer, usually the medication.

Several specific symptoms overlap. Sweating and feeling flushed can come from a hot flash or from a GLP-1's effect on digestion and blood sugar after eating. Fatigue is common both in menopause and in the early weeks of GLP-1 treatment as the body adjusts and food intake drops. Sleep disruption, including waking at night, happens in menopause due to night sweats and hormone shifts, and can also occur on GLP-1s. Nausea is mainly a GLP-1 effect but can worsen the general feeling of being unwell that menopause sometimes brings.

Because of this overlap, it helps to track symptoms carefully and to recognize that you may be managing two things at once. For example, learning to handle nausea and hot flashes together is a real and common challenge, and managing sleep disruption during this combined phase deserves its own attention. Rather than assuming the medication is causing everything, work with your provider to tease apart which symptoms come from menopause and which from the drug, since the solutions differ.

It is biologically plausible that GLP-1 medications could have some direct effect on temperature regulation, but this is not yet proven and should be treated as an open question. GLP-1 receptors exist in parts of the brain involved in appetite and, potentially, in pathways that influence body temperature and the autonomic nervous system. Some early laboratory and animal research has explored GLP-1's role in thermoregulation, but this has not translated into clear, confirmed effects on menopausal hot flashes in human studies.

At present, there are no large clinical trials designed specifically to test whether GLP-1 drugs increase or decrease hot flashes as a direct effect. Until such studies exist, any claim that these medications directly treat or worsen hot flashes goes beyond the evidence. What we can say with more confidence is the indirect link through weight loss, which is supported by human trials.

This is an area researchers are increasingly interested in, partly because so many women use GLP-1 drugs during the menopause years, and partly because of growing interest in how metabolism and menopause interact. Future studies may clarify whether there is a direct effect. For now, the practical takeaway is to focus on what is known: weight loss can ease hot flashes, GLP-1s produce weight loss, and the two conditions frequently overlap. If your hot flashes are severe, do not wait for new research; effective treatments already exist, including hormone therapy and non-hormonal options, which can be used alongside a GLP-1 under medical guidance, much like other approaches that combine weight management with menopause care.

You can manage hot flashes while on a GLP-1 by combining proven hot flash treatments with smart habits that account for taking both at once. First, treat the hot flashes directly. The most effective option is hormone therapy (HRT) for women who are appropriate candidates, and there are well-studied non-hormonal medications like fezolinetant and certain low-dose antidepressants. These can be used together with a GLP-1 under your provider's supervision, since they work through different pathways.

Lifestyle steps help too and complement your weight-loss efforts. Dress in layers you can remove, keep your bedroom cool, and identify personal triggers like alcohol, caffeine, and spicy food, which can set off both hot flashes and digestive upset on a GLP-1. Staying well hydrated supports both temperature regulation and helps with common GLP-1 side effects. Regular physical activity and good sleep hygiene improve hot flashes, mood, and energy at the same time.

Finally, pay attention to the practical realities of doing both. Make sure you are getting enough protein to protect muscle during weight loss, since menopause already increases muscle loss risk, and prioritize sleep, which both menopause and weight loss can disrupt. Keep a simple symptom log so you and your provider can adjust your plan, whether that means changing your hot flash treatment, your GLP-1 dose timing, or your daily routine. With the right combination, many women find they can lose weight and keep hot flashes under control at the same time, addressing both halves of midlife health together.